Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 55
Solid insulin market leadership position in Region Japan &
Korea
tMU
16
14
12
20
10
8
6
4
2
0
Japan & Korea insulin market by segment
Japan & Korea modern and new-generation
insulin volume market shares
Device penetration
-
MI and NGI penetration
CAGR volume¹: 0.5%
Penetration
Novo Nordisk
-
Sanofi
Eli Lilly
CAGR value¹:
(4.4%)
100%
70%
60%
80%
Fast-acting
50%
50%
60%
40%
Premix
30%
40%
20%
25%
25%
Long-acting 20%
10%
0%
0%
Nov
Nov
2012
2017
Nov
2012
Nov
2017
1 CAGR for 5-year period
MI: Modern insulin; NGI: New-generation insulin
Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 volume and value (DKK) figures
changing
diabetes®
Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 volume figures
novo nordiskView entire presentation